The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
Public ClinicalTrials.gov record NCT01655823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Dose-Finding, Placebo Controlled, Phase II Multicenter Study of Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone. Chemotherapy-induced peripheral neuropathy commonly occurs in greater than 40% of patients. To improve the peripheral neuropathy, the chemotherapy dosing is often either decreased or discontinued potentially affecting tumor responsiveness, prognosis, and survival. There is an unmet medical need for treatment of cancer patients with chemotherapy induced neuropathic pain (CINP) and the proposed study will investigate the efficacy and safety of multiple dose levels of tetrodotoxin (TTX) versus placebo in moderate to severe neuropathic pain caused by chemotherapy.
Study identification
- NCT ID
- NCT01655823
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2012 (Type not available)
- Primary completion
- Jan 2015 (Actual)
- Completion
- Feb 11, 2015 (Actual)
- Last update posted
- Oct 30, 2018
2012 – 2015
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lalita Pandit | Fountain Valley | California | 92708 | — |
| Robert Moss | Fountain Valley | California | 92708 | — |
| Alliance Research Centers | Laguna Hills | California | 92653 | — |
| Global Research Management | Los Angeles | California | 90027 | — |
| Innovative Clinical Research | Los Angeles | California | 90603 | — |
| El Camino Cancer Center | Mountain View | California | 94040 | — |
| Pacific Cancer Care | Salinas | California | 93901 | — |
| Redwood Regional Medical Group | Santa Rosa | California | 95403 | — |
| St. Vincent's Medical Center | Bridgeport | Connecticut | 06606 | — |
| Medsol Clinical Research Center | Port Charlotte | Florida | 33952 | — |
| Axcess Medical Research | Wellington | Florida | 33414 | — |
| Cancer Center of Middle Georgia | Dublin | Georgia | 31021 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| St. Louis Cancer Care | Bridgeton | Missouri | 63044 | — |
| Mercy Medical Research Institute | Springfield | Missouri | 65807 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| New Mexico Oncology Hematology Consultants | Albuquerque | New Mexico | 87103 | — |
| Signal Point Clinical Research Center | Middletown | Ohio | 45042 | — |
| Institute of Pain Research | Oklahoma City | Oklahoma | 73104 | — |
| Gettysburg Cancer Center | Gettysburg | Pennsylvania | 17325 | — |
| University of Texas Southwestern | Dallas | Texas | 75390-9179 | — |
| Jean Brown Research | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01655823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2018 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01655823 live on ClinicalTrials.gov.